Association of High‐Sensitivity C‐Reactive Protein and Lipoprotein‐Associated Phospholipase A2 with Metabolically Unhealthy Phenotype: A Cross Sectional Study

References

• Di Angelantonio E, Bhupathiraju SN, Wormser D, et al; Global, B. M. I. M. C. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet. 2016;388(10046):776–786. doi:10.1016/S0140-6736(16)30175-1
   PubMed Web of Science ®Google Scholar
• Karelis AD, Brochu M, Rabasa-Lhoret R. Can we identify metabolically healthy but obese individuals (MHO)? Diabetes Metab. 2004;30(6):569–572. doi:10.1016/S1262-3636(07)70156-8
   PubMed Web of Science ®Google Scholar
• Smith GI, Mittendorfer B, Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–3989. doi:10.1172/JCI129186
   PubMed Web of Science ®Google Scholar
• Karelis AD. Metabolically healthy but obese individuals. Lancet. 2008;372(9646):1281–1283. doi:10.1016/S0140-6736(08)61531-7
   PubMed Web of Science ®Google Scholar
• Lassale C, Tzoulaki I, Moons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J. 2018;39(5):397–406. doi:10.1093/eurheartj/ehx448
   PubMed Web of Science ®Google Scholar
• Aung K, Lorenzo C, Hinojosa MA, Haffner SM. Risk of developing diabetes and cardiovascular disease in metabolically unhealthy normal-weight and metabolically healthy obese individuals. J Clin Endocrinol Metab. 2014;99(2):462–468. doi:10.1210/jc.2013-2832
   PubMed Web of Science ®Google Scholar
• Dandona P, Mohanty P, Ghanim H, et al. The suppressive effect of dietary restriction and weight loss in the obese on the generation of reactive oxygen species by leukocytes, lipid peroxidation, and protein carbonylation. J Clin Endocrinol Metab. 2001;86(1):355–362. doi:10.1210/jcem.86.1.7150
   Web of Science ®Google Scholar
• Jakubiak GK, Osadnik K, Lejawa M, et al. Obesity and insulin resistance is the component of the metabolic syndrome most strongly associated with oxidative stress. Antioxidants. 2021;11(1). doi:10.3390/antiox11010079
   Web of Science ®Google Scholar
• Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:508409. doi:10.1155/2015/508409
   PubMed Web of Science ®Google Scholar
• Ferreira FG, Reitz LK, Valmorbida A, et al. Metabolically unhealthy and overweight phenotypes are associated with increased levels of inflammatory cytokines: a population-based study. Nutrition. 2022;96:111590. doi:10.1016/j.nut.2022.111590
   Web of Science ®Google Scholar
• Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98(10):E1610–E1619. doi:10.1210/jc.2013-2038
   PubMed Web of Science ®Google Scholar
• Succurro E, Marini MA, Frontoni S, et al. Insulin secretion in metabolically obese, but normal weight, and in metabolically healthy but obese individuals. Obesity. 2008;16(8):1881–1886. doi:10.1038/oby.2008.308
   PubMed Web of Science ®Google Scholar
• Gonzalez-Gil EM, Cadenas-Sanchez C, Santabarbara J, et al. Inflammation in metabolically healthy and metabolically abnormal adolescents: the HELENA study. Nutr Metab Cardiovasc Dis. 2018;28(1):77–83. doi:10.1016/j.numecd.2017.10.004
   Web of Science ®Google Scholar
• Constantinides A, de Vries R, van Leeuwen JJ, et al. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A(2) mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity. Eur J Intern Med. 2012;23(7):633–638. doi:10.1016/j.ejim.2012.05.008
   Web of Science ®Google Scholar
• O’Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006;113(14):1745–1752. doi:10.1161/CIRCULATIONAHA.105.612630
   Web of Science ®Google Scholar
• Anderson JL. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol. 2008;101(12A):23F–33F. doi:10.1016/j.amjcard.2008.04.015
   Web of Science ®Google Scholar
• Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004;109(7):837–842. doi:10.1161/01.CIR.0000116763.91992.F1
   PubMed Web of Science ®Google Scholar
• Zhao L, Qiu X. Higher ratio of serum uric acid to serum creatinine (SUA/SCr) increases the risk of metabolic unhealthy phenotype. Nutr Metab Cardiovasc Dis. 2023;33(10):1981–1988. doi:10.1016/j.numecd.2023.07.013
   Web of Science ®Google Scholar
• Wang Y, Zhu X, Chen Z, et al. Natural histories of metabolite BMI phenotypes and their impacts on cardiovascular disease risk over a decade-long follow-up. Obes Res Clin Pract. 2021;15(6):579–586. doi:10.1016/j.orcp.2021.10.002
   Web of Science ®Google Scholar
• Lu Y, Pechlaner R, Cai J, et al. Trajectories of age-related arterial stiffness in Chinese men and women. J Am Coll Cardiol. 2020;75(8):870–880. doi:10.1016/j.jacc.2019.12.039
   Web of Science ®Google Scholar
• World Health Organization. Western Pacific Region, International Association for the Study of Obesity. The Asia-Pacific Perspective. World Health Organization; 2000.
   Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–1645. doi:10.1161/CIRCULATIONAHA.109.192644
   PubMed Web of Science ®Google Scholar
• Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, E. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285(19):2486–2497. doi:10.1001/jama.285.19.2486
   PubMed Web of Science ®Google Scholar
• Cӑtoi AF, Parvu AE, Andreicut AD, et al. Metabolically healthy versus unhealthy morbidly obese: chronic inflammation, nitro-oxidative stress, and insulin resistance. Nutrients. 2018;10(9):1199. doi:10.3390/nu10091199
   Web of Science ®Google Scholar
• Stenzel AP, Carvalho R, Jesus P, et al. Serum antioxidant associations with metabolic characteristics in metabolically healthy and unhealthy adolescents with severe obesity: an observational study. Nutrients. 2018;10(2):150. doi:10.3390/nu10020150
   Web of Science ®Google Scholar
• Wildman RP, Kaplan R, Manson JE, et al. Body size phenotypes and inflammation in the women’s health initiative observational study. Obesity. 2011;19(7):1482–1491. doi:10.1038/oby.2010.332
   Web of Science ®Google Scholar
• Xu XJ, Gauthier MS, Hess DT, et al. Insulin sensitive and resistant obesity in humans: AMPK activity, oxidative stress, and depot-specific changes in gene expression in adipose tissue. J Lipid Res. 2012;53(4):792–801. doi:10.1194/jlr.P022905
   PubMed Web of Science ®Google Scholar
• Murano I, Barbatelli G, Parisani V, et al. Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat depots of genetically obese mice. J Lipid Res. 2008;49(7):1562–1568. doi:10.1194/jlr.M800019-JLR200
   PubMed Web of Science ®Google Scholar
• Marques-Vidal P, Velho S, Waterworth D, Waeber G, Kanel VR. The association between inflammatory biomarkers and metabolically healthy obesity depends of the definition used. Eur J Clin Nutr. 2012;66(4):426–435. doi:10.1038/ejcn.2011.170
   PubMed Web of Science ®Google Scholar
• Dennis EA, Cao J, Hsu YH, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111(10):6130–6185. doi:10.1021/cr200085w
   PubMed Web of Science ®Google Scholar
• Bonnefont-Rousselot D. La Lp-PLA2, marqueur d’inflammation vasculaire et de vulnérabilité de la plaque d’athérosclérose [Lp-PLA2, a biomarker of vascular inflammation and vulnerability of atherosclerosis plaques]. Ann Pharm Fr. 2016;74(3):190–197. French. doi:10.1016/j.pharma.2015.09.002
   Google Scholar
• Kim M, Yoo HJ, Ko J, Lee JH. Metabolically unhealthy overweight individuals have high lysophosphatide levels, phospholipase activity, and oxidative stress. Clin Nutr. 2020;39(4):1137–1145. doi:10.1016/j.clnu.2019.04.025
   Web of Science ®Google Scholar
• Chen YH, Li WC, Chen YC, et al. The correlation between lipoprotein associated phospholipase A(2) and central overweight status. Int J Immunopathol Pharmacol. 2021;35:20587384211048562. doi:10.1177/20587384211048562
   Web of Science ®Google Scholar
• Sarlon-Bartoli G, Boudes A, Buffat C, et al. Circulating lipoprotein-associated phospholipase A2 in high-grade carotid stenosis: a new biomarker for predicting unstable plaque. Eur J Vasc Endovasc Surg. 2012;43(2):154–159. doi:10.1016/j.ejvs.2011.10.009
   Web of Science ®Google Scholar
• Kolodgie FD, Burke AP, Skorija KS, et al. Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26(11):2523–2529. doi:10.1161/01.ATV.0000244681.72738.bc
   PubMed Web of Science ®Google Scholar